Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate

Share

  • 1

    Psoriasis affects 2-3% of the global population and can lead to psoriatic arthritis in up to 40% of patients, significantly impairing quality of life.

  • 2

    TWEAK, a cytokine linked to inflammation, plays a role in psoriatic disease, but its effects on treatment outcomes with adalimumab and methotrexate are not well understood.

  • 3

    This study evaluates serum TWEAK levels before and after treatment with adalimumab for psoriasis and methotrexate for psoriatic arthritis.

  • 4

    Clinical assessments included PASI for psoriasis severity and DAPSA for psoriatic arthritis activity, measured at baseline and 24 weeks.

  • 5

    The study design reflects real-world therapeutic standards, with a minimum of 20 participants per group to ensure sufficient statistical power.

Original Source(s)

Evaluation of serum TWEAK levels and treatment response in psoriasis and psoriatic arthritis: a prospective comparative case–control study of adalimumab and methotrexate

  • by Eisa M. Hegazy, Eslam Abdelfattah Sadek, Shimaa Saber Ahmed

  • March 18, 2026

Related Content

The Missing Step in Pediatric Lupus Care

Survey data show gaps between rheumatologists’ beliefs and clinical practice in screening and neuropsychological evaluation for childhood-onset systemic lupus erythematosus

Knee OA Trial Tests Diacerein

Researchers compared diacerein and placebo in a 24-week randomized study involving knee osteoarthritis with MRI-confirmed effusion-synovitis.

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.